A Single Arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of Capecitabine Plus Oxaliplatin (XELOX) in the Peri-operative Treatment of Patients With Potentially Resectable Liver Metastasis From Colorectal Cancer
To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in
the peri-operative treatment of potential resectable metastatic colorectal cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer
3.6 years
No
Feng Lin
Principal Investigator
Guangdong General Hospital
China: Ethics Committee
ML22298
NCT00997685
November 2009
October 2015
Name | Location |
---|